Profile data is unavailable for this security.
About the company
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
- Revenue in EUR (TTM)1.33m
- Net income in EUR-23.49m
- Incorporated2004
- Employees51.00
- LocationPhaxiam Therapeutics SA60 avenue RockefellerLYON 69008FranceFRA
- Phone+33 478744438
- Fax+33 478755629
- Websitehttps://erytech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IntegraGen SA | 12.54m | -171.40k | 3.50m | 55.00 | -- | 1.71 | 130.48 | 0.279 | -0.025 | -0.025 | 1.90 | 0.3041 | 1.47 | 12.06 | 4.06 | 227,953.30 | -2.01 | -1.93 | -4.78 | -4.41 | 66.41 | 65.11 | -1.37 | -1.51 | 1.57 | -- | 0.3587 | -- | -4.78 | 12.61 | -4,783.19 | -- | -- | -- |
Theranexus SA | 0.00 | -6.83m | 4.67m | 19.00 | -- | 2.10 | -- | -- | -1.09 | -1.09 | 0.00 | 0.2863 | 0.00 | -- | -- | 0.00 | -70.79 | -42.66 | -82.29 | -47.97 | -- | -- | -- | -- | -- | -1,058.68 | 0.6212 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
Acticor Biotech SA | 0.00 | -18.64m | 5.36m | 28.00 | -- | -- | -- | -- | -1.55 | -1.55 | 0.00 | -0.4028 | 0.00 | -- | -- | 0.00 | -164.53 | -- | -568.29 | -- | -- | -- | -- | -- | -- | -19.85 | 10.47 | -- | -- | -- | -17.40 | -- | -- | -- |
Phaxiam Therapeutics SA | 1.33m | -23.49m | 16.47m | 51.00 | -- | 0.4234 | -- | 12.42 | -5.14 | -5.14 | 0.2901 | 3.90 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 16.59m | 27.00 | 205.66 | 1.93 | 28.62 | 9.87 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | 62,278.52 | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
Predilife SA | 317.79k | -4.22m | 18.16m | 19.00 | -- | -- | -- | 57.15 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 18.37m | 22.00 | -- | 4.55 | -- | 17.14 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
Nfl Biosciences SAS | 0.00 | -3.75m | 19.51m | 3.00 | -- | 10.57 | -- | -- | -0.4674 | -0.4674 | 0.00 | 0.1901 | 0.00 | -- | -- | 0.00 | -117.67 | -83.27 | -292.70 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0388 | -- | -- | -- | -53.28 | -- | -- | -- |
Valbiotis SA | 4.73m | -7.37m | 20.50m | 52.00 | -- | 1.04 | -- | 4.33 | -0.5904 | -0.5904 | 0.3798 | 1.24 | 0.1564 | 3.36 | 17.83 | 91,019.23 | -24.35 | -32.92 | -33.77 | -46.36 | 48.76 | 53.15 | -155.67 | -418.87 | 3.38 | -38.19 | 0.2598 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
Poxel SA | 1.55m | -44.24m | 28.63m | 30.00 | -- | -- | -- | 18.52 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Dec 2022 | 176.27k | 1.58% |
OFI Invest Asset Management SAas of 29 Feb 2024 | 18.27k | 0.16% |
BVF Partners LPas of 28 Mar 2023 | 10.53k | 0.10% |
Generali Asset Management SGR SpAas of 30 Dec 2022 | 7.57k | 0.07% |
Gestys SAas of 28 Jun 2024 | 6.00k | 0.05% |
Friedland Gestion SASas of 26 Apr 2024 | 3.65k | 0.03% |
BBVA Asset Management SA SGIICas of 30 Jun 2024 | 1.76k | 0.02% |
Deka Investment GmbHas of 30 Jun 2024 | 509.00 | 0.01% |
DWS Investment GmbHas of 31 Dec 2022 | 0.00 | 0.00% |
Montaigne Capital SASas of 31 May 2024 | 0.00 | 0.00% |